Trials / Unknown
UnknownNCT00314912
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 650 (planned)
- Sponsor
- Bellus Health Inc. - a GSK company · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimer's disease.
Detailed description
Duration of treatment: 12 months. Patients who complete the Phase III clinical trial will be offered the opportunity to receive Tramiprosate (3APS) in an open-label extension study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tramiprosate (3APS) |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-04-17
- Last updated
- 2007-07-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00314912. Inclusion in this directory is not an endorsement.